Controlled Substances

December 11, 2023 | Controlled Substances, Legal & Legislative Research, Opioids, Prescription Drugs, Substance Abuse, Synthetic Drugs

In this survey, the Legislative Analysis and Public Policy Association (LAPPA) examines the policy response at the state level to the spread of pill presses used to create counterfeit drugs. There is relatively little policy in this area compared to federal law, and most innovation is relatively recent.  Findings are presented jurisdiction by jurisdiction for easy comparison among states and between current state- and federal law....

October 31, 2023 | Fact Sheets, Novel Psychoactive Substances, Substance Abuse, Synthetic Drugs

The Legislative Analysis and Public Policy Association (LAPPA) continues to monitor the emergence of novel psychoactive substances (NPS) appearing on the illicit drug market in the United States. The term “novel” does not denote a brand new, never-before-seen substance but rather a substance that is newly available in the drug market. This fact sheet, the sixth in a series highlighting these dangerous drugs, is an examination of bromazolam....

October 30, 2023 | Controlled Substances, Fact Sheets, Recovery, Substance Abuse, Treatments

This fact sheet summarizes a recent increase in the use of contingency management, a behavioral therapy that reinforces or rewards positive behavioral change. Often, mental health professionals use contingency management alongside other methods of treatment. In the context of substance use disorder treatment, patients typically receive something of monetary value to incentivize abstinence from drug use. Contingency management is a well-studied and effective method for treating substance use disorder, but until recently, received little support....

October 16, 2023 | Controlled Substances, First Responders, Legal & Legislative Research, Naloxone, Opioid Antagonists, Opioid Antagonists, Opioids, Public Health, Public Safety, Substance Abuse

In an effort to save lives, states have implemented laws to make it easier for first responders and the general public to obtain opioid antagonists, such as naloxone. Additionally, to encourage people to assist an individual who is or may be suffering an overdose, the majority of states also enacted laws which protect laypeople who administer opioid antagonists, in good faith, in an emergency from civil and/or criminal liability. The Legislative Analysis and Public Policy Association (LAPPA) undertook an extensive research project to determine the current status of opioid antagonist access laws throughout the United States, including the District of Columbia and all U.S. territories. As of August 2020, all 50 states and the District of Columbia have some form of an opioid antagonist access law. ...

September 18, 2023 | Fact Sheets, Novel Psychoactive Substances, Substance Abuse, Synthetic Drugs

The Legislative Analysis and Public Policy Association (LAPPA) continues to monitor the emergence of novel psychoactive substances (NPS) appearing on the illicit drug market in the United States. The term “novel” does not denote a brand new, never-before-seen substance but rather a substance that is newly available in the drug market. This fact sheet, the fifth in a series highlighting these dangerous drugs, is an examination of nitazenes....

September 14, 2023 | Controlled Substances, Fentanyl, Legal & Legislative Research, Public Health, Public Safety, Substance Abuse, Synthetic Drugs

In this survey, the Legislative Analysis and Public Policy Association (LAPPA) examines the legislative and regulatory response at the state level to the issue of fentanyl cleanup. As at the federal level, there is little policy in this area, and the only exceptions to that rule are very recent. Findings are presented jurisdiction by jurisdiction for easy comparison among the states....

August 28, 2023 | Controlled Substances, Harm Reduction, Legal & Legislative Research, Opioids, Pharmacy, Prescription Drugs, Public Health, Public Safety, Substance Abuse

In this document, the Legislative Analysis and Public Policy Association examines state-level legislative and administrative responses to the public health risk posed by expired and unused prescription medications. In the last several years, states, in coordination with the Federal Drug Enforcement Administration (DEA) have enacted legislation or promulgated administrative regulations to authorize drug take-back programs where expired or unused pharmaceuticals can be collected from the public by authorized persons and disposed of in a safe manner. Findings are presented by state for ease of comparison....

August 4, 2023 | Controlled Substances, Harm Reduction, Law Enforcement, Legal & Legislative Research, Opioids, Public Health, Public Safety, Sharps/Syringes, Substance Abuse

Syringe services programs (SSP) are harm reduction programs that provide a wide range of services including, but not typically limited to, the provision of new, unused hypodermic needles and syringes and other injection drug use supplies, such as cookers, tourniquets, alcohol wipes, and sharps waste disposal containers, to people who inject drugs. In this summary, readers will find information with respect to SSPs for each state, including citations to applicable statutes and/or regulations, whether the state allows SSPs by statute, whether there are any municipal or county ordinances or regulations in place within the state, program components, miscellaneous provisions, and information on any pending legislation....

August 4, 2023 | Controlled Substances, Criminal Justice, Medication Assisted Treatment (MAT), Opioids, Recovery, Reports & Studies, Substance Abuse, Treatments

This report from the Bureau of Justice Assistance, Office of Justice Programs, details guidelines that local government officials, jail administrators, correctional officers, and health care professionals can use in providing effective health care for adults who are sentenced or awaiting sentencing to jail, awaiting court action on a current charge, or being held in custody for other reasons....